eMedicine Specialties > Emergency Medicine > Cardiovascular
Myocardial Infarction
Updated: Oct 5, 2009
Introduction
Background
Myocardial infarction (MI) is the rapid development of myocardial necrosis caused by a critical imbalance between oxygen supply and demand of the myocardium. This usually results from plaque rupture with thrombus formation in a coronary vessel, resulting in an acute reduction of blood supply to a portion of the myocardium.
The ECG shows lateral ST-segment elevation that is consistent with a lateral wall AMI.
Although the clinical presentation of a patient is a key component in the overall evaluation of the patient with MI, many events are either "silent" or are clinically unrecognized, evidencing that patients, families, and health care providers often do not recognize symptoms of a MI. The appearance of cardiac markers in the circulation generally indicates myocardial necrosis and is a useful adjunct to diagnosis.
Cardiac markers help to categorize MI, which is considered part of a spectrum referred to as acute coronary syndrome that includes ST-elevation MI (STEMI), non–ST-elevation MI (NSTEMI), and unstable angina. This categorization is valuable because patients with ischemic discomfort may or may not have ST-segment elevations on their electrocardiogram. Those without ST elevations may ultimately be diagnosed with NSTEMI or with unstable angina based on the presence or absence of cardiac enzymes. Additionally, therapeutic decisions, such as administering an intravenous thrombolytic or performing percutaneous coronary intervention (PCI), are often made based on this categorization.
Pathophysiology
The most common cause of MI is narrowing of the epicardial blood vessels due to atheromatous plaques. Plaque rupture with subsequent exposure of the basement membrane results in platelet aggregation, thrombus formation, fibrin accumulation, hemorrhage into the plaque, and varying degrees of vasospasm. This can result in partial or complete occlusion of the vessel and subsequent myocardial ischemia. Total occlusion of the vessel for more than 4-6 hours results in irreversible myocardial necrosis, but reperfusion within this period can salvage the myocardium and reduce morbidity and mortality.
Nonatherosclerotic causes of MI include coronary vasospasm as seen in variant (Prinzmetal) angina and in patients using cocaine and amphetamines; coronary emboli from sources such as an infected heart valve; occlusion of the coronaries due to vasculitis; or other causes leading to mismatch of oxygen supply and demand, such as acute anemia from GI bleeding. MI induced by chest trauma has also been reported, usually following severe chest trauma such as motor vehicle accidents and sports injuries. For additional information, see Medscape's article " New Definition of 'MI' Poised for World Domination ".
Frequency
United States
MI is a leading cause of morbidity and mortality in the United States. Approximately 1.3 million cases of nonfatal MI are reported each year, for an annual incidence rate of approximately 600 cases per 100,000 people. The proportion of patients diagnosed with NSTEMI compared with STEMI has progressively increased.
International
Cardiovascular diseases account for 12 million deaths annually worldwide. MI continues to be a significant problem in industrialized countries and is becoming an increasingly significant problem in developing countries.
Mortality/Morbidity
Approximately 500,000-700,000 deaths are caused by ischemic heart disease annually in the United States.
One third of patients who experience STEMI die within 24 hours of the onset of ischemia, and many of the survivors experience significant morbidity. For many patients, the first manifestation of coronary artery disease is sudden death likely from malignant ventricular dysrhythmia.
- More than one half of deaths occur in the prehospital setting.
- In-hospital fatalities account for 10% of all deaths. An additional 10% of deaths occur in the first year postinfarction.
- A steady decline has occurred in the mortality rate from STEMI over the last several decades. This appears to be due to a combination of a fall in the incidence of MI (replaced in part by an increase in the incidence of unstable angina) and a reduction in the case-fatality rate once an MI has occurred.
Sex
A male predilection exists in persons aged 40-70 years. Evidence exists that women more often have MIs without atypical symptoms. The atypical presentation in women might explain the sometimes delayed diagnosis of MIs in women.
In persons older than 70 years, no sex predilection exists.
Age
MI most frequently occurs in persons older than 45 years.
Certain subpopulations younger than 45 years are at risk, particularly cocaine users, persons with type 1 diabetes mellitus, patients with hypercholesterolemia, and those with a positive family history for early coronary disease. A positive family history includes any first-degree male relative aged 45 years or younger or any first-degree female relative aged 55 years or younger who experienced a myocardial infarction. In younger patients, the diagnosis may be hampered if a high index of suspicion is not maintained.
Clinical
History
The history is critical in making the diagnosis of MI and sometimes may provide the only clues that lead to the diagnosis in the initial phases of the patient presentation.
- Chest pain, usually across the anterior precordium is typically described as tightness, pressure, or squeezing.
- Pain may radiate to the jaw, neck, arms, back, and epigastrium. The left arm is more frequently affected; however, a patient may experience pain in both arms.
- Dyspnea, which may accompany chest pain or occur as an isolated complaint, indicates poor ventricular compliance in the setting of acute ischemia. Dyspnea may be the patient's anginal equivalent, and, in an elderly person or a patient with diabetes, it may be the only complaint.
- Nausea, abdominal pain, or both often are present in infarcts involving the inferior or posterior wall.
- Anxiety
- Lightheadedness with or without syncope
- Cough
- Nausea with or without vomiting
- Diaphoresis
- Wheezing
- Elderly patients and those with diabetes may have particularly subtle presentations and may complain of fatigue, syncope, or weakness. The elderly may also present with only altered mental status. Those with preexisting altered mental status or dementia may have no recollection of recent symptoms and may have no complaints whatsoever.
- As many as half of MIs are clinically silent in that they do not cause the classic symptoms described above and consequently go unrecognized by the patient. A high index of suspicion should be maintained for MI especially when evaluating women, patients with diabetes, older patients, patients with dementia, and those with a history of heart failure. Patients with a permanent pacemaker in place may confound recognition of STEMI by 12-lead ECG due to the presence of paced ventricular contractions.
Physical
The physical examination can often be unremarkable.
- Patients with ongoing symptoms usually lie quietly in bed and appear pale and diaphoretic.
- Hypertension may precipitate MI, or it may reflect elevated catecholamine levels due to anxiety, pain, or exogenous sympathomimetics.
- Hypotension may indicate ventricular dysfunction due to ischemia. Hypotension in the setting of MI usually indicates a large infarct secondary to either decreased global cardiac contractility or a right ventricular infarct.
- Acute valvular dysfunction may be present. Valvular dysfunction usually results from infarction that involves the papillary muscle. Mitral regurgitation due to papillary muscle ischemia or necrosis may be present.
- Rales may represent congestive heart failure.
- Neck vein distention may represent pump failure. With right ventricular failure, cannon jugular venous a waves may be noted.
- Third heart sound (S3) may be present.
- A fourth heart sound is a common finding in patients with poor ventricular compliance that is due to preexisting heart disease or hypertension.
- Dysrhythmias may present as an irregular heartbeat or pulse.
- Low-grade fever is not uncommon.
Causes
The most frequent cause of myocardial infarction (MI) is rupture of an atherosclerotic plaque within a coronary artery with subsequent arterial spasm and thrombus formation.
Other causes include the following:
- Coronary artery vasospasm
- Ventricular hypertrophy (eg, left ventricular hypertrophy [LVH], idiopathic hypertrophic subaortic stenosis [IHSS], underlying valve disease)
- Hypoxia due to carbon monoxide poisoning or acute pulmonary disorders (Infarcts due to pulmonary disease usually occur when demand on the myocardium dramatically increases relative to the available blood supply.)
- Coronary artery emboli, secondary to cholesterol, air, or the products of sepsis
- Cocaine, amphetamines, and ephedrine
- Arteritis
- Coronary anomalies, including aneurysms of the coronary arteries
- Increased afterload or inotropic effects, which increase the demand on the myocardium
- Aortic dissection, with retrograde involvement of the coronary arteries
- Although rare, pediatric coronary artery disease may be seen with Marfan syndrome, Kawasaki disease, Takayasu arteritis, progeria, and cystic medial necrosis (see Myocardial Infarction in Childhood).
Risk factors for atherosclerotic plaque formation include the following:
- Age
- Male gender
- Smoking
- Hypercholesterolemia and hypertriglyceridemia, including inherited lipoprotein disorders
- Diabetes mellitus
- Poorly controlled hypertension
- Type A personality
- Family history
- Sedentary lifestyle
More on Myocardial Infarction |
 Overview: Myocardial Infarction |
| Differential Diagnoses & Workup: Myocardial Infarction |
| Treatment & Medication: Myocardial Infarction |
| Follow-up: Myocardial Infarction |
| Multimedia: Myocardial Infarction |
| References |
| Next Page » |
References
[Best Evidence] Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. Aug 27 2009;361(9):858-67. [Medline].
[Best Evidence] Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ. May 19 2009;338:b1807. [Medline].
Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. May 30 2009;373(9678):1849-1860. [Medline]. [Full Text].
Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. Jun 25 2009;360(26):2705-18. [Medline].
Abbott BG, Wackers FJ. Use of radionuclide imaging in acute coronary syndromes. Curr Cardiol Rep. Jan 2003;5(1):25-31. [Medline].
[Guideline] AHA with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7: the era of reperfusion: section 1: acute coronary syndromes (acute myocardial infarction). The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. Aug 22 2000;102(8 Suppl):I172-203. [Medline].
Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. Sep 2000;36(3):959-69. [Medline].
Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. Aug 21 2003;349(8):733-42. [Medline].
[Guideline] Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. Aug 4 2004;44(3):671-719. [Medline].
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. Oct 31 1996;335(18):1342-9. [Medline].
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. Aug 28 1999;354(9180):716-22. [Medline].
Bholasingh R, de Winter RJ, Fischer JC, Koster RW, Peters RJ, Sanders GT. Safe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MB(mass). Heart. Feb 2001;85(2):143-8. [Medline].
Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet. Mar 8 2003;361(9360):847-58. [Medline].
[Guideline] Braunwald. Management of Patients with Unstable Angina and ST-Segment Elevation MI, A report of the ACC/AHA Task Force on Practice Guidelines. November 2002.
Brogan GX Jr, Vuori J, Friedman S, McCuskey CF, Thode HC Jr, Vaananen HK, et al. Improved specificity of myoglobin plus carbonic anhydrase assay versus that of creatine kinase-MB for early diagnosis of acute myocardial infarction. Ann Emerg Med. Jan 1996;27(1):22-8. [Medline].
Brown AL, Mann NC, Daya M, Goldberg R, Meischke H, Taylor J, et al. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients. Rapid Early Action for Coronary Treatment (REACT) study. Circulation. Jul 11 2000;102(2):173-8. [Medline].
de Torbal A, Boersma E, Kors JA, van Herpen G, Deckers JW, van der Kuip DA, et al. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J. Mar 2006;27(6):729-36. [Medline].
Fesmire FM, Hughes AD, Fody EP, Jackson AP, Fesmire CE, Gilbert MA, et al. The Erlanger chest pain evaluation protocol: a one-year experience with serial 12-lead ECG monitoring, two-hour delta serum marker measurements, and selective nuclear stress testing to identify and exclude acute coronary syndromes. Ann Emerg Med. Dec 2002;40(6):584-94. [Medline].
FTT Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. Feb 5 1994;343(8893):311-22. [Medline].
[Best Evidence] Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. Dec 29 2005;353(26):2758-68. [Medline].
Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med. Mar 11 1993;328(10):685-91. [Medline].
GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. Feb 22 1986;1(8478):397-402. [Medline].
Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. Mar 11 1993;328(10):673-9. [Medline].
GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med. Oct 16 1997;337(16):1118-23. [Medline].
GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. Sep 2 1993;329(10):673-82. [Medline].
Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials. N Engl J Med. Nov 28 1996;335(22):1660-7. [Medline].
International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group. Lancet. Jul 14 1990;336(8707):71-5. [Medline].
Kannel WB. Silent myocardial ischemia and infarction: insights from the Framingham Study. Cardiol Clin. Nov 1986;4(4):583-91. [Medline].
Kwong RY, Schussheim AE, Rekhraj S, Aletras AH, Geller N, Davis J, et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation. Feb 4 2003;107(4):531-7. [Medline].
Newby LK, Rutsch WR, Califf RM, Simoons ML, Aylward PE, Armstrong PW, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol. Jun 1996;27(7):1646-55. [Medline].
Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. Oct 31 1996;335(18):1333-41. [Medline].
Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, Weaver WD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol. Dec 1 1999;84(11):1281-6. [Medline].
Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. Dec 2000;36(7):2056-63. [Medline].
[Guideline] Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. Nov 1 1996;28(5):1328-428. [Medline].
Saleh SS, Hannan EL, Ting L. A multistate comparison of patient characteristics, outcomes, and treatment practices in acute myocardial infarction. Am J Cardiol. Nov 1 2005;96(9):1190-6. [Medline].
Schömig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med. Aug 10 2000;343(6):385-91. [Medline].
Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med. Feb 22 1996;334(8):481-7. [Medline].
[Guideline] Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. Jan 3 2006;47(1):216-35. [Medline].
SPEED Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation. Jun 20 2000;101(24):2788-94. [Medline].
Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. Oct 6 1993;270(13):1589-95. [Medline].
Tsai TN, Yang SP, Tsao TP, Huang KA, Cheng SM. Delayed diagnosis of post-traumatic acute myocardial infarction complicated by congestive heart failure. J Emerg Med. Nov 2005;29(4):429-31. [Medline].
Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. May 1999;137(5):786-91. [Medline].
Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. Feb 1997;29(2):229-36. [Medline].
Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. Jul 15 2003;108(2):135-42. [Medline].
Wilcken DE. Overview of inherited metabolic disorders causing cardiovascular disease. J Inherit Metab Dis. 2003;26(2-3):245-57. [Medline].
Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. Sep 3 1988;2(8610):525-30. [Medline].
World Health Organization. Third Monitoring Report of the World Health Organization. 1991-93.
Yuichi S, Takako I, Fumio I, Akihiro Y, Takahiro F, Toshiyuki H, et al. Detection of atherosclerotic coronary artery plaques by multislice spiral computed tomography in patients with acute coronary syndrome: report of 2 cases. Circ J. Mar 2004;68(3):263-6. [Medline].
Zeymer U, Tebbe U, Essen R, Haarmann W, Neuhaus KL. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Am Heart J. Jan 1999;137(1):34-8. [Medline].
Further Reading
Keywords
signs of myocardial infarction, symptoms of myocardial infarction, non stemi myocardial infarction, MI, acute myocardial infarction, AMI, heart attack, chest pain, hypertension, mitral regurgitation, dysrhythmias, acute valvular dysfunction, congestive heart failure, CHF, third heart sound, fourth heart sound, heart block, emboli, right ventricular failure, cannon jugular venous a waves, left ventricular hypertrophy, coronary artery vasospasm, acute coronary syndrome
